2LUCESOLI F, CALIGIURI M, BOTERTI MF, et al. Dose-dependent increase of oxidative damage in the testes of rats subjected to acute iron overload[J]. Archives Biochem Biophys, 1999,372(1) :37-43.
3HILLMAN RS. Chapter 54 Hematopoietic agents[A]. HARDMAN JG, LIMBIRD LE. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed[M]. McGraw-Hill Company, 2001.1454.
4BERRY CC, WELLS S, CHARLES S, et al. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro [J]. Biomaterials,2003, 24(25 ) :4551-4557.
5KNIGHT B, BOWEN LH, GEREMAN RD, et al. Comparison of the core size distribution in iron dextran complexes using Mossauer spectroscopy and X-ray diffraction[J]. J Inorg Biochem, 1999,73(4) :227-233.
6KUNATH K, von HAPRE A, PETERSEN H, et al. The structure of PEG-modified poly (ethylene imines ) influences biodistribution and pharrnacokinetics of their complexes with NF-kappaB decoy in mice[J]. Pharm Res, 2002, 19(6): 810-817.
7GAUR U, SAHOO SK, DE TK, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system[J]. Int J Pharm,2002,202(1-2) :1-10.
8BARTFAY WJ, DAWOOD F, WEN WH, et al. Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron -overload[J]. Cardiovas Res, 1999,43 (4): 892 -900.
9DIMITRIOU E, KAIRIS M, SARAFIDOU J, et al. Iron overload and kidney lysosomes[J]. Biochem Biophy Acta, 2000,1501 ( 2-3 ): 138-148.
